Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Sep 11;77(5):779-787.
doi: 10.1093/cid/ciad278.

Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial

Naokatsu Ando  1 , Daisuke Mizushima  1 , Kazumi Omata  2 , Takashi Nemoto  3 , Natsumi Inamura  3 , Saori Hiramoto  3 , Misao Takano  1 , Takahiro Aoki  1 , Koji Watanabe  1 , Haruka Uemura  1 , Daisuke Shiojiri  1 , Yasuaki Yanagawa  1 , Junko Tanuma  1 , Katsuji Teruya  1 , Yoshimi Kikuchi  1 , Hiroyuki Gatanaga  1 , Shinichi Oka  1
Affiliations
Randomized Controlled Trial

Combination of Amoxicillin 3000 mg and Probenecid Versus 1500 mg Amoxicillin Monotherapy for Treating Syphilis in Patients With Human Immunodeficiency Virus: An Open-Label, Randomized, Controlled, Non-Inferiority Trial

Naokatsu Ando et al. Clin Infect Dis. .

Abstract

Background: Amoxicillin plus probenecid is an alternative to intramuscular benzathine penicillin G for treating syphilis in the United Kingdom. Low-dose amoxicillin is an alternative treatment option used in Japan.

Methods: We conducted an open-label, randomized, controlled, non-inferiority trial between 31 August 2018, and 3 February 2022, to compare 1500 mg low-dose amoxicillin monotherapy with the combination of 3000 mg amoxicillin and probenecid (non-inferiority margin 10%). Patients with human immunodeficiency virus (HIV) infection and syphilis were eligible. The primary outcome was the cumulative serological cure rate within 12 months post-treatment, measured using the manual rapid plasma reagin card test. Secondary outcomes included safety assessment.

Results: A total of 112 participants were randomized into 2 groups. Serological cure rates within 12 months were 90.6% and 94.4% with the low-dose amoxicillin and combination regimens, respectively. Serological cure rates for early syphilis within 12 months were 93.5% and 97.9% with the low-dose amoxicillin and combination regimens, respectively. Non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid overall and for early syphilis was not confirmed. No significant side effects were detected.

Conclusions: This is the first randomized controlled trial to demonstrate a high efficacy of amoxicillin-based regimens for treating syphilis in patients with HIV infection, and the non-inferiority of low-dose amoxicillin compared with amoxicillin plus probenecid was not seen. Therefore, amoxicillin monotherapy could be a good alternative to intramuscular benzathine penicillin G with fewer side effects. However, further studies comparing with benzathine penicillin G in different populations and with larger sample sizes are needed.

Trials registration: (UMIN000033986).

Keywords: Treponema pallidum; amoxicillin; human immunodeficiency virus; syphilis.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest . K. T. reports payment for lectures from Shionogi Pharmaceutical. S. O. reports research grants to institution from ViiV Healthcare and Gilead Sciences; honoraria for lectures to author from ViiV Healthcare, Gilead Sciences, MSD. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Comment in

Publication types

MeSH terms

LinkOut - more resources